Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Personalized cancer drug delivery could soon be a reality

Imagine the day a machine can draw your blood, screen it for genetic mutations and chemical variations that can cause cancer, and pop out a drug tailor-made for your DNA.

1 Oct 2010

CPEX Pharmaceuticals initiates reviewing strategic alternatives to maximize shareholder value

CPEX Pharmaceuticals, Inc. today announced that its Board of Directors is continuing its previously announced process to review strategic alternatives to maximize shareholder value. The strategic alternatives the Board of Directors is reviewing include, but are not limited to, a sale, merger or other business combination of CPEX with a third party or a monetization of CPEX's assets including its rights to receive royalties and milestone payments.

30 Sep 2010

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.

30 Sep 2010

Starpharma expands partnership with Eli Lilly

Starpharma Holdings Limited (ASX:SPL,OTCQX:SPHRY) today announced the signing of a collaborative research agreement with leading US pharmaceutical corporation Eli Lilly and Company.

29 Sep 2010

Apricus Biosciences prices securities offering

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that it has entered into agreements with selected investors to sell up to 1,728,882 Units at a price per Unit of $5.40, for aggregate gross proceeds of approximately $9.3 million.

29 Sep 2010

Crocker Ventures announces acquisition of TMJ Implants

Crocker Ventures today announced that it has acquired TMJ Implants of Golden, Colo., the leading manufacturer of implants for the treatment of temporomandibular joint (TMJ) disorder.

29 Sep 2010

Generex Biotechnology receives new patent for buccal drug delivery system

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has been awarded a new patent in Canada.

29 Sep 2010

C-CCNE receives grant to improve cancer treatment using nanotechnology

The National Cancer Institute has awarded a five-year, $13.6 million grant to the University of North Carolina at Chapel Hill's Carolina Center of Cancer Nanotechnology Excellence (C-CCNE) based at the UNC Lineberger Comprehensive Cancer Center, for research to improve the diagnosis and treatment of cancer through applying/using advances in nanotechnology.

28 Sep 2010

Stirling Products’ drug delivery technology interests big ‘pharma’

Healthcare group, Stirling Products Limited (ASX:STI) has advised that following the recent TeleMedCare e-health acquisition and the conditional addition of the recently announced pathology business (subject to due diligence completion and shareholder approval), the Company is now in process of its strategised business integration.

26 Sep 2010

3M announces series of educational events to combat healthcare-associated infections

As a company on a mission to help hospitals fight healthcare-associated infections (HAIs), 3M Infection Prevention today announced a series of educational events taking place the week of September 27.

24 Sep 2010

Balsamic rub cream now available in innovative dispensing stick

Laboratorios Cinfa launched in the Spanish market Respirub and Respirub infantil, a non-greasy, clean balsamic rub cream available in an innovative dispensing stick.

24 Sep 2010

InspireMD to launch MGuard Prime MicroNet stent system at TCT Conference

InspireMD, developers of the novel MGuard(TM) coronary MicroNet stent system, will introduce MGuard Prime at its booth #2052 at the TCT Conference in Washington DC, September 23-25, 2010. MGuard Prime presents an advanced Co-Cr Design of 80 micron struts along with InspireMD's unique MicroNet(R) Mesh Technology.

23 Sep 2010

RXi, EyeGate collaborate to develop RNAi therapeutics for retinal disorders

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, and EyeGate Pharma, the leader in non-invasive ocular drug delivery announced today that they will collaborate on the ocular delivery of RNAi therapeutics. Each party will contribute technology, expertise, and resources to the collaboration.

23 Sep 2010

Generex presents study results of Oral-lyn insulin spray at EASD Annual Meeting

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it is presenting study results at the 46th Annual Meeting of the European Association for the Study of Diabetes being held in Stockholm, Sweden, 20 - 24 September, 2010.

23 Sep 2010

Intarcia Therapeutics presents ITCA 650 phase 2 study results for type 2 diabetes

Intarcia Therapeutics, Inc. presented today final results of a 24-week phase 2 clinical study of ITCA 650 (DUROS continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden.

23 Sep 2010

pSivida reports $8.8 million consolidated net income for 2010 fiscal year

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back of the eye diseases, including the product candidate Iluvien for the treatment of Diabetic Macular Edema, today announced financial results for its fourth quarter and fiscal year ended June 30, 2010.

23 Sep 2010

Titan completes enrollment in Probuphine Phase 3 study for opioid addiction

Titan Pharmaceuticals, Inc. today announced that patient enrollment is now complete in the confirmatory, Phase 3 clinical study of Probuphine for the treatment of opioid addiction. This placebo and active controlled Phase 3 study is being conducted at 20 sites in the United States and the results are expected in the second quarter of 2011, about three months ahead of the original schedule.

22 Sep 2010

Phase I/II DIGNITY trial abstract of ThermoDox accepted for poster session at 2010 Breast Cancer Symposium

Celsion Corporation announced today that an abstract on its Phase I/II DIGNITY trial of ThermoDox in Recurrent Chest Wall Breast Cancer has been accepted for a poster session at the 2010 Breast Cancer Symposium. The abstract will provide updated clinical results, as well as the rationale and design of the DIGNITY study, which is evaluating ThermoDox in combination with microwave hyperthermia in women with RCW Breast Cancer.

22 Sep 2010

FDA guides Apricus Bio on RayVa's approvability for Raynaud's syndrome secondary to scleroderma

Apricus Biosciences, backed by a revenue-generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, announced today that the U.S. Food and Drug Administration (FDA) has provided guidance on the clinical requirements for assessing the approvability of RayVa for the treatment of Raynaud's syndrome secondary to scleroderma.

22 Sep 2010

Merus partners with Innocoll to launch 3 advanced wound care products in Canada

Merus Labs International Inc. is pleased to announce that their wholly owned subsidiary, Merus Labs Inc. announces the execution of a definitive agreement with Innocoll Pharmaceuticals Limited to license in, on an exclusive basis, 3 advanced wound care products for the Canadian market. Furthermore, Innocoll agrees to grant to Merus a right of first refusal for all current pipeline advanced wound care products for the Canadian Market.

22 Sep 2010